International Stem Cell Corporation (ISCO)
USD 0.12
(20.0%)
USD 0.12
(20.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 2.59 Million USD | -26.69% |
| 2022 | 3.53 Million USD | -9.43% |
| 2021 | 3.9 Million USD | 7.32% |
| 2020 | 3.63 Million USD | 22.35% |
| 2019 | 2.97 Million USD | 206.29% |
| 2018 | 970 Thousand USD | 419.08% |
| 2017 | -304 Thousand USD | -176.36% |
| 2016 | -110 Thousand USD | -104.27% |
| 2015 | 2.57 Million USD | 332.04% |
| 2014 | -1.11 Million USD | 50.47% |
| 2013 | -2.24 Million USD | -242.97% |
| 2012 | -654 Thousand USD | 39.83% |
| 2011 | -1.08 Million USD | 80.35% |
| 2010 | -5.53 Million USD | -1060.17% |
| 2009 | -476.82 Thousand USD | -254.23% |
| 2008 | 309.17 Thousand USD | 286.99% |
| 2007 | -165.34 Thousand USD | 96.46% |
| 2006 | -4.67 Million USD | 0.0% |
| 2005 | - USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 2.75 Million USD | 6.53% |
| 2024 Q2 | 2.82 Million USD | 2.25% |
| 2023 Q4 | 2.59 Million USD | -6.67% |
| 2023 Q2 | 2.84 Million USD | -13.98% |
| 2023 Q1 | 3.31 Million USD | -6.28% |
| 2023 Q3 | 2.77 Million USD | -2.56% |
| 2023 FY | 2.59 Million USD | -26.69% |
| 2022 FY | 3.53 Million USD | -9.43% |
| 2022 Q2 | 3.72 Million USD | -5.08% |
| 2022 Q3 | 3.62 Million USD | -2.55% |
| 2022 Q1 | 3.91 Million USD | 0.46% |
| 2022 Q4 | 3.53 Million USD | -2.54% |
| 2021 Q2 | 3.63 Million USD | -8.72% |
| 2021 Q3 | 3.34 Million USD | -7.9% |
| 2021 FY | 3.9 Million USD | 7.32% |
| 2021 Q4 | 3.9 Million USD | 16.66% |
| 2021 Q1 | 3.97 Million USD | 9.44% |
| 2020 Q4 | 3.63 Million USD | 8.64% |
| 2020 Q1 | 3.11 Million USD | 4.75% |
| 2020 Q2 | 3.11 Million USD | 0.1% |
| 2020 Q3 | 3.34 Million USD | 7.42% |
| 2020 FY | 3.63 Million USD | 22.35% |
| 2019 Q4 | 2.97 Million USD | 16.51% |
| 2019 Q3 | 2.55 Million USD | 3.2% |
| 2019 Q2 | 2.47 Million USD | 258.12% |
| 2019 FY | 2.97 Million USD | 206.29% |
| 2019 Q1 | 690 Thousand USD | -28.87% |
| 2018 Q4 | 970 Thousand USD | 15.61% |
| 2018 FY | 970 Thousand USD | 419.08% |
| 2018 Q2 | 623 Thousand USD | 742.27% |
| 2018 Q1 | -97 Thousand USD | 68.09% |
| 2018 Q3 | 839 Thousand USD | 34.67% |
| 2017 Q4 | -304 Thousand USD | -113.88% |
| 2017 Q3 | 2.19 Million USD | 27.18% |
| 2017 Q2 | 1.72 Million USD | 173.77% |
| 2017 FY | -304 Thousand USD | -176.36% |
| 2017 Q1 | 629 Thousand USD | 671.82% |
| 2016 Q3 | -733 Thousand USD | 4.56% |
| 2016 Q4 | -110 Thousand USD | 84.99% |
| 2016 FY | -110 Thousand USD | -104.27% |
| 2016 Q2 | -768 Thousand USD | 50.19% |
| 2016 Q1 | -1.54 Million USD | -159.38% |
| 2015 FY | 2.57 Million USD | 332.04% |
| 2015 Q4 | 2.59 Million USD | 14.76% |
| 2015 Q3 | 2.26 Million USD | 32.49% |
| 2015 Q2 | 1.7 Million USD | 379.54% |
| 2015 Q1 | -611 Thousand USD | 45.0% |
| 2014 FY | -1.11 Million USD | 50.47% |
| 2014 Q2 | -748 Thousand USD | 24.52% |
| 2014 Q3 | -471 Thousand USD | 37.03% |
| 2014 Q4 | -1.11 Million USD | -135.88% |
| 2014 Q1 | -991 Thousand USD | 55.82% |
| 2013 Q1 | -1.91 Million USD | -192.35% |
| 2013 Q2 | -654 Thousand USD | 65.79% |
| 2013 Q3 | -1.79 Million USD | -174.01% |
| 2013 Q4 | -2.24 Million USD | -25.17% |
| 2013 FY | -2.24 Million USD | -242.97% |
| 2012 Q3 | -2.13 Million USD | 47.21% |
| 2012 Q4 | -654 Thousand USD | 69.3% |
| 2012 FY | -654 Thousand USD | 39.83% |
| 2012 Q1 | -5.76 Million USD | -430.17% |
| 2012 Q2 | -4.03 Million USD | 29.98% |
| 2011 Q2 | -3.33 Million USD | 34.06% |
| 2011 Q1 | -5.05 Million USD | 8.66% |
| 2011 Q3 | -2.33 Million USD | 29.94% |
| 2011 Q4 | -1.08 Million USD | 53.44% |
| 2011 FY | -1.08 Million USD | 80.35% |
| 2010 Q3 | -5.7 Million USD | 22.67% |
| 2010 Q4 | -5.53 Million USD | 3.08% |
| 2010 FY | -5.53 Million USD | -1060.17% |
| 2010 Q1 | -2.26 Million USD | -375.39% |
| 2010 Q2 | -7.38 Million USD | -225.63% |
| 2009 Q3 | -136.53 Thousand USD | 84.88% |
| 2009 Q2 | -903.24 Thousand USD | -28.11% |
| 2009 Q1 | -705.02 Thousand USD | -328.04% |
| 2009 FY | -476.82 Thousand USD | -254.23% |
| 2009 Q4 | -476.82 Thousand USD | -249.25% |
| 2008 Q4 | 309.17 Thousand USD | 174.65% |
| 2008 Q2 | 678.58 Thousand USD | 578.59% |
| 2008 Q1 | 100 Thousand USD | 160.48% |
| 2008 FY | 309.17 Thousand USD | 286.99% |
| 2008 Q3 | -414.16 Thousand USD | -161.03% |
| 2007 Q2 | -2.65 Million USD | 38.87% |
| 2007 Q3 | -1.03 Million USD | 61.07% |
| 2007 Q4 | -165.34 Thousand USD | 84.02% |
| 2007 FY | -165.34 Thousand USD | 96.46% |
| 2007 Q1 | -4.34 Million USD | 6.94% |
| 2006 FY | -4.67 Million USD | 0.0% |
| 2006 Q3 | - USD | 0.0% |
| 2006 Q2 | - USD | 0.0% |
| 2006 Q1 | - USD | 0.0% |
| 2006 Q4 | -4.67 Million USD | 0.0% |
| 2005 FY | - USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1310.00 USD | 197809.924% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 54.146% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 93.948% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | 1137.577% |
| Rebus Holdings, Inc. | 305 Thousand USD | -749.18% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 141.082% |
| Qrons Inc. | 351.42 Thousand USD | -636.995% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 622.36 Thousand USD | -316.155% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 94.037% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | 12791.102% |
| Skye Bioscience, Inc. | -5.72 Million USD | 145.269% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 83.569% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | 37.106% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -544.521% |
| SQZ Biotechnologies Company | -36.23 Million USD | 107.147% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | -15.51% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | -179.34% |
| Mesoblast Limited | 55.85 Million USD | 95.363% |
| Marizyme, Inc. | 18.56 Million USD | 86.052% |
| Genus plc | 190.6 Million USD | 98.641% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | -15.841% |
| Pharming Group N.V. | 109.8 Million USD | 97.641% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | -201.078% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | -113.364% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | -280.882% |
| ContraFect Corporation | -6.02 Million USD | 142.98% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | -1823.663% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | -124.159% |
| IMV Inc. | 7.67 Million USD | 66.234% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 52.925% |
| MultiCell Technologies, Inc. | 90.04 USD | -2876399.334% |
| ONE Bio Corp. | 9.04 Million USD | 71.35% |
| Accustem Sciences Inc. | -733.97 Thousand USD | 452.872% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 79.994% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 1.36 Million USD | -89.331% |
| Q BioMed Inc. | 4.06 Million USD | 36.207% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 91.523% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | -157.017% |
| Biomind Labs Inc. | 711.4 Thousand USD | -264.07% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 95.722% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | -29.539% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 79.776% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -620.024% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | -1752.594% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | -12936.694% |
| Curative Biotechnology, Inc. | 2.2 Million USD | -17.621% |
| GB Sciences, Inc. | 1.74 Million USD | -48.227% |
| Alpha Cognition Inc. | -183.78 Thousand USD | 1509.232% |
| HST Global, Inc. | 96.79 Thousand USD | -2575.813% |
| CSL Limited | 10.52 Billion USD | 99.975% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | -1155.959% |
| Halberd Corporation | 144.72 Thousand USD | -1689.65% |
| Enzolytics Inc. | 981.65 Thousand USD | -163.84% |
| Agentix Corp. | 37.63 Thousand USD | -6782.623% |
| Resverlogix Corp. | 6.45 Million USD | 59.851% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | 484.793% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | -2.02 Billion USD | 100.128% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 105.509% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 63.371% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 4.379% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 129.299% |
| AVAX Technologies, Inc. | -5.9 Million USD | 143.874% |
| Zenith Capital Corp. | 10.06 Thousand USD | -25635.294% |
| Genscript Biotech Corporation | -1.06 Billion USD | 100.244% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | -1192.209% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | -8.548% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | -1474.382% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | 14239.098% |
| Kadimastem Ltd | -253.1 Thousand USD | 1123.303% |
| Helix BioMedix, Inc. | -2.57 Million USD | 200.777% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 87.226% |
| BioStem Technologies, Inc. | 4.47 Million USD | 42.084% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 201.25 Thousand USD | -1186.931% |
| LadRx Corporation | -2.03 Million USD | 227.181% |
| Cell Source, Inc. | 9.23 Million USD | 71.945% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -307.767% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -307.767% |
| NovAccess Global Inc. | 2.17 Million USD | -18.891% |
| Affymax, Inc. | -5.59 Million USD | 146.275% |
| Itoco Inc. | 228.3 Thousand USD | -1034.447% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | -1804.566% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 47.751% |
| Mobile Lads Corp. | 484.23 Thousand USD | -434.868% |
| CytoDyn Inc. | 20.26 Million USD | 87.217% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | 400409.119% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | 28044.594% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 66.39% |
| SYBLEU INC | 473.71 Thousand USD | -446.743% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 41.889% |
| Bioxytran, Inc. | 1.89 Million USD | -36.394% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -4049.776% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | -18.758% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 3.43 Million USD | 24.578% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 69.718% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 772.6 Thousand USD | -235.229% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | 307.2% |
| Neutra Corp. | 52.18 Thousand USD | -4862.922% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | 204.058% |
| PureTech Health plc | -167.19 Million USD | 101.549% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | 1157.54% |
| IXICO plc | -4.44 Million USD | 158.273% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 80.407% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 95.278% |
| CSL Limited | 10.52 Billion USD | 99.975% |
| Cellectis S.A. | -43.81 Million USD | 105.911% |